Overall responses and time to progression by BCL2:BCL2L1 gene expression. Presented are the response data for (A) all patients and (B) those with t(11;14) who had evaluable samples for BCL2 and BCL2L1 gene expression by droplet digital PCR. ORR indicates a response of PR or better. Time to progression is shown for (C) all patients and (D) those with t(11;14) who had evaluable samples. Per panel C, median time to progression for 10 patients with a high BCL2:BCL2L1 ratio was 11.5 months. For 34 patients with a low BCL2:BCL2L1 ratio, median time to progression was 1.9 months. All patients, with high or low ratios, who responded to treatment had t(11;14). Per panel D, median time to progression for 9 patients with t(11;14) and a high BCL2:BCL2L1 ratio was 11.5 months. Of 15 patients with t(11;14) and a low BCL2:BCL2L1 ratio, median time to progression was 5.3 months.